龚正说，面向未来，上海的目标非常明确，就是按照习近平主席和中央政府对上海发展的战略定 位，到2035年基本建成具有世界影响力的社会主义现代化国际大都市。未来五年，是实现这一宏伟目标 的关键时期。上海将始终秉承"开放、创新、包容"的城市品格，以开放拥抱全球，以创新追求卓越，以 包容共谋发展，奋力开创发展新局面。要聚力加快"五个中心"建设，强化"五个中心"核心功能，深 化"五个中心"联动发展，持续提升城市能级和核心竞争力。聚力培育发展新质生产力，增强科技创新能 力，促进产业转型升级，打造高水平人才高地，点燃高质量发展澎湃引擎。聚力实施高水平改革开放， 稳步扩大制度型开放，深入推进长三角一体化发展，持续深化营商环境改革，充分激发城市发展活力。 聚力推进现代化人民城市建设，打造宜居安居的品质生活，打造绿色低碳的美丽上海，打造便捷高效的 智慧城市，打造安全可靠的韧性城市，提高城市治理现代化水平。期待聆听各位成员和嘉宾的真知灼 见，帮助我们开阔视野、拓宽思路，谋划好面向2030年的发展战略。热忱欢迎更多国际企业来沪投资兴 业，与上海这座梦想之城携手并进、共享机遇、共赢未来。 会上，瑞士洛桑国际管理学院教授马克·格瑞文、华 ...

IMF更新全球经济展望，美联储公布褐皮书。 上周国际市场风云变幻，关税阴云再起，黄金再迎里程碑。美股全线下挫，道指周跌2.73%，纳指周跌 2.53%，标普500指数周跌2.43%。欧洲三大股指表现不佳，英国富时100指数周跌0.67%，德国DAX 30 指数周跌0.56%，法国CAC 40指数周跌2.02%。 本周看点颇多，市场持续关注美国政府停摆的相关进展以及美联储是否会释放进一步降息的信号。若停 摆持续，更多经济数据可能会延迟发布，此外多位美联储官员将发表例行讲话。在欧洲，通胀数据将影 响未来政策路径走向，英国与澳大利亚将公布关键就业数据。世界银行和国际货币基金组织（IMF）的 秋季年会召开，届时将公布最新经济展望。美股新财报季拉开帷幕，大型银行将率先亮相。 鲍威尔再亮相 美国劳工统计局于上周五证实，原定于下周发布的9月消费者价格指数（CPI）报告，将调整至美国东 部时间10月24日（周五）上午8点30分发布。因联邦预算僵局，美国劳工统计局失去资金支持，员工被 迫离岗。美国劳工统计局在一份声明中指出，9月物价数据将是特例，在政府停摆问题解决前，该局不 会发布其他任何数据。 本周内计划发布但同样可能延迟的 ...

Get ahead of the market by subscribing to Seeking Alpha's Wall Street Week Ahead, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports, and conference presentations. Stock index futures edged higher on Friday, following a pause in Wall Street's rally as concerns grew over the ongoing U.S. government shutdown. On Thursday, major indexes ended lower as momentum faded. The ...

Core Insights - The article discusses the concept of Dividend Kings, which are companies that have increased their dividends for over 50 consecutive years, highlighting their resilience and consistent growth in dividends [4] Group 1: Dividend Kings Overview - Dividend Kings are companies that have a long history of increasing dividends, making them attractive for long-term income investors [4][7] - The article emphasizes the importance of selecting companies with a positive consensus from analysts, focusing on stability and growth potential [1][2] Group 2: Company Profiles AbbVie Inc. (ABBV) - AbbVie reported a revenue increase of approximately 3.7% to $56.33 billion, but net income declined by 12% to around $4.28 billion, resulting in a basic EPS of $2.40 for 2024 [12] - The forward dividend payout is $6.56, with a yield of 6.56% and a payout ratio of 59.92% [13] - Analysts rate AbbVie as a Moderate Buy with a score of 4.21 out of 5, indicating a potential upside of 21.38% from its current price [14][15] Johnson & Johnson (JNJ) - Johnson & Johnson's revenue rose roughly 4.3% to $88.82 billion, but net income declined nearly 60% due to a discontinued operation, resulting in a basic EPS of $5.84 [18] - The forward dividend payout is $5.20, yielding 5.2% with a payout ratio of 49.88% [20] - Analysts rate JNJ as a Moderate Buy with a score of 4.04 out of 5, suggesting an upside potential of 11.5% [21][22] Lowe's Companies (LOW) - Lowe's revenue declined 3% to $83.67 billion, with net income down approximately 10% to $6.96 billion, leading to a basic EPS of $12.25 [26] - The forward dividend is $4.80, yielding 4.80% with a payout ratio of 38.46% [28] - Analysts rate Lowe's as a Moderate Buy with a score of 4.21 out of 5, with a potential upside of 38.5% [29][30] Abbott Laboratories (ABT) - Abbott's revenue increased by 4.5% to $41.95 billion, and net income surged 134% to $13.4 billion, resulting in a basic EPS of $7.67 [33] - The company has declared 399 consecutive quarterly dividends and has increased its payout for 51 consecutive years, with a current yield of 1.77% [34] - Analysts rate Abbott as a Strong Buy with a score of 4.43, indicating a potential upside of 19.2% [36] Coca-Cola Company (KO) - Coca-Cola's revenue for FY'24 was just over $47 billion, up 2.8%, while net income declined slightly by 0.8%, with a basic EPS of $2.47 [38] - The forward dividend is $2.04 annually, yielding just over 3%, with a 21.25% increase in dividends over the past five years [40] - Analysts rate Coca-Cola as a Strong Buy with a score of 4.76, suggesting an upside potential of 28% [40]

Core Insights - Wall Street is entering earnings season with reports from major financial institutions such as Wells Fargo, Goldman Sachs, Citigroup, Bank of America, Morgan Stanley, and JPMorgan expected [1] - Despite a significant sell-off on Friday, there is an expectation that the market's multi-year rally is not over [1] Earnings Reports - Earnings season begins on Tuesday with Blackrock, Wells Fargo, and Goldman Sachs reporting; all three have performed well this year and are not heavily impacted by the trade war [3] - Johnson & Johnson and Domino's Pizza will also report on Tuesday, with expectations for Johnson & Johnson to have the best quarter in its sector, while Domino's may miss estimates [4] - On Wednesday, Bank of America, Morgan Stanley, and Abbott Laboratories will report; Morgan Stanley has shown positive results recently, and Abbott is considered reliable [4] - Thursday will see earnings from Taiwan Semiconductor, CSX, and Charles Schwab, with positive figures expected from Taiwan Semiconductor, which supplies chips to Nvidia and AMD [6] - American Express and SLB will report on Friday; American Express shares typically decline post-earnings, while SLB management is known for transparency [7] Market Context - The week is complicated by a sharp decline in Treasury yields, which usually indicates better economic conditions ahead, but current sentiment is negative [2] - Salesforce's annual conference begins on Monday, and clarity on President Trump's new tariffs on China is anticipated, following threats of a significant increase in tariffs on Chinese imports [2]

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Markets: Stocks were selling off to close the week after President Donald Trump threatened a "massive" tariff increase on China amid a dispute over rare earth minerals. Over the summer, Trump cautioned that he would place steeper tariffs on China if it curbed exports of rare earth magnets. This announcement, however, still surprised the m ...

Wall Street analysts forecast that Abbott (ABT) will report quarterly earnings of $1.30 per share in its upcoming release, pointing to a year-over-year increase of 7.4%. It is anticipated that revenues will amount to $11.41 billion, exhibiting an increase of 7.3% compared to the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.1% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projection ...

Core Insights - Abbott Laboratories (ABT) is set to report its third-quarter 2025 results on October 15, with adjusted earnings per share (EPS) of $1.26 in the last quarter, exceeding the Zacks Consensus Estimate by 0.8% [1][8] Revenue and EPS Estimates - The Zacks Consensus Estimate for Q3 revenues is $11.42 billion, reflecting a 7.4% increase from the previous year [2][8] - The Zacks Consensus Estimate for EPS is $1.30, indicating a 7.4% improvement from the prior year's figure [2][8] Segment Performance Expectations - **Diagnostics**: Revenue growth is expected to be impacted by a decline in COVID-19 testing revenues and volume-based procurement programs in China, with a projected decrease of 4.4% year over year [3][4] - **Established Pharmaceuticals (EPD)**: Strong performance is anticipated across key markets, with a year-over-year revenue increase of 9%, driven by biosimilars as a new growth pillar [5][6] - **Medical Devices**: Expected growth of 13.3% year over year, supported by the Diabetes Care division and the integration of Libre CGM data into Epic's EHR systems [6][11] - **Nutrition**: Anticipated revenue growth of 6.3% year over year, driven by strong sales of adult nutrition brands like Ensure and Glucerna [12] Recent Developments - Abbott's Structural Heart segment is expected to see growth from surgical valves and transcatheter products, bolstered by recent CE Mark and FDA approvals [9][11] - The Rhythm Management arm is gaining traction with the leadless AVEIR pacemaker, supported by favorable clinical data [10] Earnings ESP and Zacks Rank - Abbott has an Earnings ESP of 0.00% and currently holds a Zacks Rank of 3, indicating a neutral outlook for beating estimates [13]

Financial Reporting Schedule - Next week will see significant financial reporting from major companies including JPMorgan Chase & Co., Wells Fargo & Company, and Goldman Sachs Group Inc., which will report pre-market on Tuesday [1] - Johnson & Johnson will also report alongside the financial institutions on Tuesday, indicating a blend of financial and healthcare sector updates [1] - The financial reporting theme continues with Bank of America Corporation and Morgan Stanley on Wednesday, along with ASML Holding N.V. and Abbott Laboratories, highlighting a diverse range of sectors [1] - Thursday will feature Taiwan Semiconductor Manufacturing Company Ltd. reporting pre-market, emphasizing the importance of the tech sector in the financial landscape [1] - American Express Company will lead the final wave of financial reports on Friday, rounding out a week heavy with financial disclosures [1]

本文转载自"新华社"，智通财经编辑：徐文强。 何立峰表示，中国经济基础稳、优势多、韧性强、潜能大，长期向好的支撑条件和基本趋势没有变。中 国将持续扩大高水平对外开放，欢迎跨国企业扩大在华投资，深化对华合作，共享发展机遇。 跨国公司负责人表示看好中国经济前景，将继续深耕中国市场，进一步扩大对华合作。 新华社北京10月10日电(记者董雪) 中共中央政治局委员、国务院副总理何立峰10日下午会见美国雅培公 司、英国保诚集团、韩国SK集团等知名跨国公司负责人，就全球和中国经济形势、扩大对华投资等交 换意见。 ...